

## **IDEX Biometrics ASA: Mandatory notification of trade and disclosure of large shareholding**

Reference is made to the announcement by IDEX Biometrics ASA (the "Company") on 29 April 2026, regarding the completion of a private placement of 9,696,969 shares at NOK 8.25 per share into two tranches (the "Private Placement"), and to the announcement by the Company on 6 May 2026 regarding the registration of share capital increase.

Following registration of the share capital increase pertaining to tranche 1 of the Private Placement, 5,589,059 shares have been redelivered to Anders Storbråten, the CEO of the Company (the "Share Lender") pursuant to the share lending agreement as described in the stock exchange announcement on 29 April 2026.

Notification of the redelivery of shares in accordance with the Market Abuse Regulation article 19 is attached to this announcement.

Following the redelivery of borrowed shares, the Share Lender's holding of 2,638,546 ordinary shares in the Company (of which 761,914 ordinary shares is held directly, and 1,876,632 shares is held through Pinchcliffe AS), will be increased to 8,227,605 ordinary shares in the Company, constituting respectively 3.69% and 11.50% of the share capital and votes outstanding in the Company. Consequently, the Share Lender's total registered holding of shares will cross above the 5% and 10% thresholds pursuant to section 4-2 (1) of the Norwegian Securities Trading Act. The above calculations have been made based on a total of 71,513,159 outstanding shares in the Company currently registered in the Norwegian Register of Business Enterprises (the "NRBE").

The remaining 812,137 shares pertaining to tranche 1 of the Private Placement (i.e., the shares in excess of the 5,589,059 shares redelivered to the Share Lender) have been issued on a separate, unlisted ISIN and will only be tradable on Euronext Oslo Børs following approval and publication of a listing prospectus as approved by the Norwegian Financial Supervisory Authority, expected during Q2 2026. Following such approval and publication of the prospectus, the remaining 812,137 shares will be redelivered to the Share Lender.

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation Article 19 and section 4-2 and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Anders Storbråten, CEO and CFO

Tel: +47 416 38 582

E-mail: [ir@idexbiometrics.com](mailto:ir@idexbiometrics.com)



**PRESS RELEASE**  
06 May 2026 22:40:00 CEST

#### ABOUT IDEX BIOMETRICS ASA

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

#### **Attachments**

[20260506 MAR Redelivery Of Shares \(T1\)](#)